QUEST DIAGNOSTICS INCORPORATED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 138.4 USD | +0.19% |
|
+0.76% | +0.39% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 9.45B | Sales 2025 * | 9.76B | Capitalization | 15.38B |
|---|---|---|---|---|---|
| Net income 2024 * | 894M | Net income 2025 * | 962M | EV / Sales 2024 * | 2.06 x |
| Net Debt 2024 * | 4.07B | Net Debt 2025 * | 3.5B | EV / Sales 2025 * | 1.93 x |
| P/E ratio 2024 * |
17.7
x | P/E ratio 2025 * |
16.3
x | Employees | 44,000 |
| Yield 2024 * |
2.09% | Yield 2025 * |
2.15% | Free-Float | 68.24% |
More Fundamentals
* Assessed data
More news
Latest transcript on Quest Diagnostics Incorporated
More recommendations
More press releases
More news
| 1 day | +0.19% | ||
| 1 week | +0.76% | ||
| Current month | +0.17% | ||
| 1 month | +5.17% | ||
| 3 months | +9.22% | ||
| 6 months | +4.22% | ||
| Current year | +0.39% |
1 week
135.35
138.96
1 month
125.42142.46
Current year
123.04143.63
1 year
119.59145.58
3 years
119.59174.16
5 years
73.02174.16
10 years
56.27174.16
| Managers | Title | Age | Since |
|---|---|---|---|
James Davis
CEO | Chief Executive Officer | 61 | 13-03-31 |
Sam Samad
DFI | Director of Finance/CFO | 54 | 22-07-10 |
Kristin Wallace
CMP | Compliance Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Denise Morrison
BRD | Director/Board Member | 70 | 19-02-17 |
Timothy Ring
BRD | Director/Board Member | 66 | 11-12-06 |
Gail Wilensky
BRD | Director/Board Member | 80 | 96-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.84% | 0 M€ | +12.39% | - | |
| 2.17% | 0 M€ | +9.27% | ||
| 2.05% | 0 M€ | +4.88% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 138.4 | +0.19% | 569,562 |
| 24-05-09 | 138.2 | +1.48% | 588,254 |
| 24-05-08 | 136.1 | -0.58% | 612,360 |
| 24-05-07 | 136.9 | +0.96% | 637,785 |
| 24-05-06 | 135.6 | -1.27% | 750,586 |
Delayed Quote Nyse, May 10, 2024 at 04:00 pm EDT
More quotes
Quest Diagnostics is the world's leading provider of diagnostics testing and information service for patients and health professionals. Net sales break down by activity as follows:
- testing and diagnostic services (97.3%): routine clinical testing, gene-based testing and advanced diagnostic and anatomica pathology diagnostic services;
- other (2.7%).
Calendar
2024-05-16
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
138.4
USD
Average target price
146.7
USD
Spread / Average Target
+6.01%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.39% | 15.38B | |
| +20.68% | 85.55B | |
| -29.31% | 70.07B | |
| +9.65% | 29.06B | |
| -8.63% | 17.51B | |
| +2.14% | 17.39B | |
| +6.47% | 13.4B | |
| +68.23% | 12.42B | |
| +6.43% | 12.77B | |
| +31.27% | 12.06B |
- Stock Market
- Equities
- DGX Stock